---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-033870"
form_type: "8-K"
ticker: "SION"
cik: "0002036042"
company_name: "Sionna Therapeutics, Inc."
filed_at: "2026-05-12T11:08:37+00:00"
generated_at: "2026-05-12T11:10:32.033064+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719

## Summary
- Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.
- R&D expenses $19.0M (vs. $13.7M), G&A expenses $10.6M (vs. $6.0M) year-over-year.
- Cash and equivalents $289.9M; expected to fund operations into 2028.
- Phase 2a POC trial of SION-719 fully enrolled; topline data expected summer 2026.
- Phase 1 dual-combination trial of SION-451 also on track for topline data summer 2026.

## SEC filing metadata
- accession: 0001628280-26-033870
- form_type: 8-K
- ticker: SION
- cik: 0002036042
- company_name: Sionna Therapeutics, Inc.
- filed_at: 2026-05-12T11:08:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/0001628280-26-033870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/sion-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-033870
- JSON: https://secwatch.observer/filing/0001628280-26-033870.json
- Plain text: https://secwatch.observer/filing/0001628280-26-033870.txt

## Key facts
- Earnings Releases
  Sionna Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $26.8 million.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss was $26.8 million
  - Result: reported results
  source text: Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/0001628280-26-033870-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.